Keros Therapeutics (KROS)
(Delayed Data from NSDQ)
$55.80 USD
-1.52 (-2.65%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $58.00 +2.20 (3.94%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Keros Therapeutics, Inc. (KROS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$92.00 | $105.00 | $76.00 | 60.50% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Keros Therapeutics, Inc. comes to $92.00. The forecasts range from a low of $76.00 to a high of $105.00. The average price target represents an increase of 60.5% from the last closing price of $57.32.
Analyst Price Targets (8 )
Broker Rating
Keros Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, 10 are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 10 | 10 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/8/2024 | William Blair | Matt Phipps | Strong Buy | Strong Buy |
8/8/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
8/7/2024 | Wells Fargo Securities | Tiago Fauth | Strong Buy | Strong Buy |
8/7/2024 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
6/25/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/18/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
6/18/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Tyler Van Buren | Strong Buy | Strong Buy |
1/19/2024 | BTIG | Julian Harrison | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 10 |
Average Target Price | $92.00 |
LT Growth Rate | 4.80% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -1.26 |
KROS FAQs
Keros Therapeutics, Inc. (KROS) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms.
The average price target for Keros Therapeutics, Inc. (KROS) is $92.00. The current on short-term price targets is based on 8 reports.
The forecasts for Keros Therapeutics, Inc. (KROS) range from a low of $76 to a high of $105. The average price target represents a increase of $64.87 from the last closing price of $55.80.
The current UPSIDE for Keros Therapeutics, Inc. (KROS) is 64.87%
Based on short-term price targets offered by eight analysts, the average price target for Keros Therapeutics, Inc. comes to $92.00. The forecasts range from a low of $76.00 to a high of $105.00. The average price target represents an increase of 60.5% from the last closing price of $57.32.